ID
Neonatal Herpes Simplex Virus
search
Neonatal Herpes Simplex Virus
, Neonatal HSV, Congenital Herpes Simplex Virus
See Also
Genital Herpes
Neonatal Sepsis
Herpes Simplex Encephalitis
Epidemiology
Incidence
: 1 per 3,000 to 20,000 live U.S. births
Prevalence
of
HSV II
seropositivity in U.S. adults: 25%
HSV seroconversion during pregnancy: 2-3%
Pathophysiology
Vertical transmission from mother
Vaginal Delivery
with active
Genital Herpes
lesions
Highest risk if primary HSV outbreak in third trimester
Risk of transmission during primary HSV outbreak: 33%
Risk of transmission during secondary HSV: 3%
Many women are asymptomatic
In known Neonatal HSV, only 30% mothers symptomatic
Risk Factors
Maternal HSV at time of delivery (highest risk)
HSV is asymptomatic in nearly two thirds of mothers
Exercise
a low clinical threshold for testing
Fetal scalp electrode use
Vaginal Delivery
Precautions
Poor outcomes are seen even with early diagnosis, but outcomes are worse with delayed diagnosis
Exercise
a low threshold in starting
Acyclovir
when Neonatal HSV is considered
Neonatal HSV presentations are often cryptic
Fever
may be sole presentation with absent
Vesicle
s
Mother is frequently asymptomatic at time of delivery
Findings
Irritability
Fever
Lethargy
Poor feeding
Ill appearing newborn
Signs
Perinatal Transmission
Vesicular Lesions onset at ~21 weeks of life
Skin HSV lesions absent in 50% of disseminated cases
Eye or mouth HSV vesicular lesions
HSV Encephalitis
Other disseminated HSV infection sites
Lung
Liver
Adrenal Gland
s
Signs
Congenital
HSV I
nfection (in utero transmission)
Microcephaly
Hydrocephalus
Chorioretinitis
Hepatomegaly
Helps differentiate from
Erythema Toxicum Neonatorum
Labs
Culture sites (repeat weekly)
Culture vesicular fluid for HSV
Culture any vesicular rash in infant under 2 months
Blood Culture
for HSV
Urine Culture
for HSV
CSF Culture
and PCR for HSV
HSV Culture of fluid from Eyes, nose and mucosa
Liver
transaminases (ALT, AST)
Management
Consider rule-out
Neonatal Sepsis
protocol concurrently
Start
Acyclovir
early and with a low threshold
Fever
and CSF
Pleocytosis
confers a 1% risk of
HSV Encephalitis
Acyclovir
30 mg/kg/day IV every 8 hours
Duration of
Antiviral
therapy
Local involvement (e.g. eyes): 14 days
Disseminated or CNS involvement: Per local
Consultation
Complications
Neonatal Seizure
disorder
Psychomotor retardation
Spasticity
Learning Disability
Blindness
Prognosis
Mortality
Localized (Skin, eyes, mouth): No increased mortality
HSV Encephalitis
: 15% mortality
Disseminated HSV: 57% mortality
References
Claudius in Majoewsky (2012) EM:Rap 12(11): 7-8
Kohl in Behrman (2000) Nelson Pediatrics, p. 966-72
Kimberlin (2001) Pediatrics 108(2):223-9 [PubMed]
Kimberlin (2001) Pediatrics 108(2):230-8 [PubMed]
Rudnick (2002) Am Fam Physician 65(6):1338-42 [PubMed]
Snyder (2024) Am Fam Physician 109(3): 212-6 [PubMed]
Type your search phrase here